A highly anticipated clinical trial from Eli Lilly showed its Type 2 diabetes drug met its primary endpoints. CNBC’s Meg Tirrell joins ‘Squawk Box’ to break down the results.
You May Also Like
About the Author: Chaz Cutler
My name is Chasity. I love to follow the stock market and financial news!